Latest News
Sagimet Biosciences Inc.
- Form 8K Sagimet Biosciences Inc For: 22 October By Investing.com
- Sagimet Biosciences Updates Pipeline: Acne Phase 3 Underway, TVB-3567 Phase 2 Planned
- Sagimet begins U.S. phase 3 trial for acne treatment denifanstat By Investing.com
- Sagimet Biosciences: The U.S. Acne Trial Is A Replication Exercise, Not A Discovery Bet
- CEO of Sagimet Biosciences shares where denifanstat could fit in acne treatment | 2026 Fall Clinical Derm
- Sagimet presents 52-week acne drug data at dermatology meeting By Investing.com
- Sagimet Biosciences (SGMT) Slips 3.15% to $9.07 as Shares Drift Toward Lower Support - Runaway Gap
- Sagimet Biosciences Announces Pricing of $115.0 Million
- Sagimet stock surges on positive acne trial data
- Sagimet Announces Positive Full 52-Week Results from
- Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat
- United Therapeutics, Sagimet drop after Goldman Sachs Sell ratings
Headlines from the last 30 days, linking to the original publishers. See all market news →